Literature DB >> 17488492

Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted.

Darren M Roberts, Jason A Roberts.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17488492      PMCID： PMC2206394          DOI： 10.1186/cc5786

Source DB:  PubMed          Journal:  Crit Care        ISSN： 1364-8535            Impact factor:   9.097


× No keyword cloud information.
  2 in total

1.  Grading quality of evidence and strength of recommendations.

Authors:  David Atkins; Dana Best; Peter A Briss; Martin Eccles; Yngve Falck-Ytter; Signe Flottorp; Gordon H Guyatt; Robin T Harbour; Margaret C Haugh; David Henry; Suzanne Hill; Roman Jaeschke; Gillian Leng; Alessandro Liberati; Nicola Magrini; James Mason; Philippa Middleton; Jacek Mrukowicz; Dianne O'Connell; Andrew D Oxman; Bob Phillips; Holger J Schünemann; Tessa Tan-Torres Edejer; Helena Varonen; Gunn E Vist; John W Williams; Stephanie Zaza
Journal:  BMJ       Date:  2004-06-19

Review 2.  Managing an effective treatment for neuroleptic malignant syndrome.

Authors:  Udo Reulbach; Carmen Dütsch; Teresa Biermann; Wolfgang Sperling; Norbert Thuerauf; Johannes Kornhuber; Stefan Bleich
Journal:  Crit Care       Date:  2007       Impact factor: 9.097
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.